Professional paper
https://doi.org/10.20471/LO.2019.47.02-03.12
First-line treatment of ovarian cancer FIGO stages IIIB-IV: focus on therapy with bevacizumab - our experience
Kristina Katić
; Department of Gynaecology and Obstetrics, University Hospital Centre Zagreb, Zagreb, Croatia
Višnja Matković
; Department of Gynaecology and Obstetrics, University Hospital Centre Zagreb, Zagreb, Croatia
Joško Lešin
; Department of Gynaecology and Obstetrics, University Hospital Centre Zagreb, Zagreb, Croatia
Goran Vujić
; Department of Gynaecology and Obstetrics, University Hospital Centre Zagreb, Zagreb, Croatia
Pavao Planinić
; Department of Gynaecology and Obstetrics, University Hospital Centre Zagreb, Zagreb, Croatia
Ante Ćorušić
; Department of Gynaecology and Obstetrics, University Hospital Centre Zagreb, Zagreb, Croatia
Abstract
Epithelial ovarian cancer is the seventh most common cancer among women and the leading cause of gynecological cancer related deaths in Croatia. Approximately 70% of patients are diagnosed at an advanced stage of the disease (FIGO III and IV). The usual approach to treatment involves complete surgical cytoreduction (R0), followed by combined platinumbased chemotherapy. Bevacizumab is recommended to add to paclitaxel/carboplatin chemotherapy in patients diagnosed at FIGO IIIB and IIIC stage with residual disease after surgery and all patients FIGO IV stage of disease, which can extend the time to progression of the disease in these patients.
In this retrospective study, we analyzed the medical data of 98 patients with newly diagnosed advanced FIGO IIIB-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer treated at the Department of Gynecology and Obstetrics in the University Hospital Centre Zagreb in the period from January 2017 to December 2018. We have analyzed the followingdata: age, ECOG status, FIGO stage of disease, principle of surgery, pathohistological type of the tumor, number and type of adjuvant chemotherapy, application of bevacizumab, number of bevacizumab cycles, side effects related to bevacizumab therapy.
Data from 98 patients were obtained. The median age was 60 years. The most patients were ECOG status 0-1 (78 %). According to the pathohistological findings, 89 % of patients had serous carcinoma, 5% endometrioid carcinoma, 3% mucinous carcinoma, 1% clear cell carcinoma, 1% borderline tumors and 1% poorly differentiated epithelial carcinoma. Most of the patients (68.5%) were underwent to primary cytoreduction, 12% “interval debulking” operation, whereas biopsy was performed in only 19.5% patients. HIPEC during surgery had 6% of patients. Resection without residual disease was achieved in only 25.5% of patients underwent surgery, while in others were reported macroscopic residual disease after surgery. 87% of patients were treated with chemotherapy with paclitaxel and carboplatin in three weeks schedule. 38 patients received antiangiogenetic drug bevacizumab. After exclusion of patients with a poor general condition (ECOG 2-4) and patients with FIGO stage IIIB and IIIC without residual disease after surgery, the percentage of patients receiving bevacizumab was 56% in 2017 and 75% in 2018. The average number of received cycles was 13 (range 1-22), and 8 patients continued the therapy in May 2019. Sixty-eight percent of the patients which received bevacizumab did not have any side effects associated with the bevacizumab therapy. The most common side effects associated with the bevacizumab were hypertension, development of deep vein thrombosis, ileus and proteinuria.
In Croatia, since February 2017, we have the possibility of using bevacizumab for the treatment of newly diagnosed ovarian cancer patients stage IV or incompletely resected patients stages III B and III C. Our results are in concordance with the literature data and show that we can safely add bevacizumab to the first line chemotherapy of advanced ovarian cancer.
Keywords
ovarian cancer; advanced stage of the disease; therapy; bevacizumab
Hrčak ID:
233621
URI
Publication date:
28.1.2020.
Visits: 3.121 *